Jiangsu wuzhong(SH:600200)2018-10-29 16:00Financial Performance - Operating revenue decreased by 41.29% to CNY 1,398,239,798.67 for the year-to-date period[6] - Net profit attributable to shareholders increased by 13.30% to CNY 115,127,766.55 year-to-date[6] - The company's operating revenue decreased by 41.29% to 139,823.98 million, primarily due to the exclusion of revenue from Suzhou Xingrui Precious Metals Materials Co., Ltd. after equity transfer in the first half of 2017[12] - Operating costs fell by 52.42% to 91,202.10 million, also reflecting the exclusion of costs from Suzhou Xingrui Precious Metals Materials Co., Ltd.[13] - Sales expenses increased by 56.33% to 30,577.51 million, mainly due to higher marketing expenses incurred by pharmaceutical subsidiaries to expand market presence[13] - Investment income surged by 605.21% to 13,301.55 million, primarily from the sale of 21,910,885 shares of Jiangsu Bank[13] - The company reported a net loss from non-operating activities of CNY 19,926,184.04 year-to-date[10] - The company reported a total profit of approximately $37.48 million for Q3, down 22.4% from $48.33 million in the same period last year[34] - The company reported a net profit of approximately $118.74 million for the first nine months, an increase of 13.2% compared to $105.00 million in the same period last year[34] Cash Flow and Liquidity - Cash flow from operating activities increased by 98.33% to CNY 175,002,271.26 year-to-date[6] - The net cash flow from operating activities rose by 98.33% to 17,500.23 million, driven by increased advance payments received from real estate projects[13] - The company reported a net cash flow from operating activities of CNY 175,002,271.26, an increase from CNY 88,236,476.58 in the same period last year[41] - Cash and cash equivalents at the end of the period totaled CNY 759,958,201.29, compared to CNY 665,842,110.78 at the end of the previous year[42] - Cash inflow from financing activities was 435,000,000.00 RMB, a substantial increase from 110,000,000.00 RMB in the same period last year[45] - Net cash flow from financing activities improved to 235,400,430.81 RMB, compared to a negative cash flow of -2,385,011.68 RMB in the previous year[45] Assets and Liabilities - Total assets increased by 8.37% to CNY 5,022,549,091.41 compared to the end of the previous year[6] - Current liabilities rose to ¥1,953,112,224.82, compared to ¥1,478,318,585.06, marking an increase of about 32.3%[25] - Total liabilities increased to ¥2,126,883,687.32 from ¥1,703,188,237.01, representing a growth of about 24.9%[26] - Owner's equity decreased to ¥2,895,665,404.09 from ¥2,931,393,150.79, reflecting a decline of about 1.22%[26] - Total current assets increased to ¥855,017,062.48 from ¥727,637,448.67, showing a growth of about 17.5%[29] Shareholder Information - The number of shareholders reached 70,976 by the end of the reporting period[9] - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 17.01% of the shares[9] Research and Development - Government subsidies related to new drug research and development amounted to CNY 11,229,189.87 year-to-date[10] - The company is in the process of obtaining approval for a new anti-cancer drug, with the project currently in the technical review phase by the National Drug Review Center[14] - R&D expenses for Q3 were approximately $5.89 million, a significant decrease of 43.5% from $10.44 million year-over-year[33] Investment Activities - The company has committed to invest 270,000,000 RMB in the Nanchang Suwu Health Industry Management Center, with an initial payment of 121,000,000 RMB made by October 20, 2018[20] - The company received 138,289,190.98 RMB from investment recoveries, with no comparable figure from the previous year[44] - Total cash inflow from investment activities reached 269,242,580.64 RMB, significantly up from 34,150,337.53 RMB year-on-year[44] Other Financial Metrics - The weighted average return on equity rose by 0.50 percentage points to 3.96%[6] - Basic earnings per share increased by 13.48% to CNY 0.160[6] - The company reported a total comprehensive income for Q3 was approximately -$7.55 million, compared to -$0.39 million in the same period last year[35] - Tax expenses for the first nine months were CNY 20,597,491.24, compared to a tax benefit of CNY 5,546,579.51 in the previous year[37]